Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Illumina, Qiagen, Agilent, and More

Illumina TruSight Oncology 500

Illumina has launched TruSight Oncology 500 (TSO 500), a pan-cancer assay to identify known and emerging biomarkers. The assay, which is for research use only and will start shipping in the first quarter of 2019, uses both DNA and RNA from tumor samples to identify somatic variants, including small variants, gene fusions, and splice variants. It can also measure tumor mutational burden and microsatellite instability. The assay covers a large number of genes as well as 1.94 megabases of the genome to measure TMB.


Qiagen GeneRead QiaAct Panels and QiaSeq TMB Panel

Qiagen has launched two new GeneRead QiaAct panels for use on its GeneReader NGS System, as well as a new QiaSeq panel for use on any next-generation sequencing system to measure tumor mutational burden.

The GeneRead QiaAct Actionable Insights Tumor DNA UMI panel broadens coverage from 12 to 30 genes influencing development and progression of the most widespread cancers, including lung, melanoma, prostate and other solid tumors. The workflow targets more than 850 DNA variants in hotspot regions as well as 125 full exons.

The GeneRead QiaAct BRCA Advanced UMI panel enables analysis of the full exon coding sequences of the BRCA1, BRCA2, TP53 and PTEN genes, which play key roles in the development and progression of breast, ovarian and other cancers. The workflow will enable alignment with National Comprehensive Cancer Network guidelines on the need for comprehensive testing that encompasses full BRCA1/2 sequencing and detection of large gene rearrangements, Qiagen said.

The QiaSeq TMB Panel is designed to run on any commercial NGS platform, and the workflow targets variants in 486 genes covering full exons. In a single panel, QiaSeq TMB detects tumor mutational burden, microsatellite instability, single nucleotide variants, and indels.


Agilent Technologies Agilent OnePGT

Agilent Technologies has launched Agilent OnePGT, a genome-wide, next-generation sequencing solution for preimplantation genetic testing. OnePGT allows parallel detection of multiple monogenic disorders, translocations, and aneuploidies from a single biopsy, going from biopsy to a single comprehensive report in a matter of days, Agilent said. The test is run on the company's Alissa platform, allowing for automatic calling of genetic abnormalities with built-in quality control metrics and an audit trail. This solution provides fertility specialists more comprehensive PGT data in order to help them identify the most viable embryos for transfer.


For more new products and services, please visit the New Products page on our website.